Immune Control Mechanisms over EBV Infection

  • A. B. Rickinson
Part of the Experimental Biology and Medicine book series (EBAM, volume 20)


The sequencing of the Epstein-Barr virus (EBV) genome (1) hopened the way to identify the complete spectrum of virus-coded proteins and to determine what controls their expression in infected cells. As the number of known viral proteins increases so one can begin to define ever more precisely the spectrum of immune response which the virus infection elicits in vivo. This catalogueing process is already well underway with respect to the anti-viral antibody response, where immunoblot analysis of serological reactivities is now complementing the original immunofluorescence methods which the pioneering work of the Henle did so much to establish. Identifying the antigenic specificity of EBV-induced T cell responses is less well advanced, but ultimately the same kind of precise analysis should be possible for the cellular response as for that mediated by antibodies. Faced with an infectious agent which can encode between 50 and 1 potential antigens, one should ask which of these many proteins are actually targets of effective immune responses i.e. those responses which have the potential either to prevent the initial virus infection or to control the numbers of virus-infected cell which accumulate in vivo.


Infectious Mononucleosis Lytic Cycle Epithelial Site Epithelial Cell Interaction Virus Latent Gene Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Baer et al., Nature 310, 207 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    J. W. Sixbey et al., New Eng. J. Med. 310, 1225 (1984).PubMedCrossRefGoogle Scholar
  3. 3.
    J. S. Greenspan et al., New Eng. J. Med. 313, 1564 (1985).PubMedCrossRefGoogle Scholar
  4. 4.
    W. Henle and G. Henle, in The Epstein-Barr Virus, M. A. Epstein and B. G. Achong Eds. (Springer-Verlag, Berlin, Heidelberg, New York, 1979) pp 61–78.Google Scholar
  5. 5.
    G. J. Hoffman, S. G. Lazarowitz, S. D. Hayward, Proc. Natl. Acad. Sci. U.S.A. 77, 2979 (1980).PubMedCrossRefGoogle Scholar
  6. 6.
    B. C. Strnad et al., J. Virol. 41, 258 (1982).PubMedGoogle Scholar
  7. 7.
    G. R. Pearson et al., J. Natl. Canc. Inst. 45, 989 (1978).Google Scholar
  8. 8.
    D. McGeoch, A. J. Davison, Nucleic Acids Res. 14, 4281 (1986).PubMedCrossRefGoogle Scholar
  9. P. J. Farrell, in Advancesin Viral Oncology, G. Klein Ed. (Raven Press, New York) in press.Google Scholar
  10. 10.
    T. Dambaugh et al., in The Epstein-Barr Virus: Recent Advances, M. A. Epstein and B. G. Achong Eds. (William Heinemann, London, 1986) pp 13–45.Google Scholar
  11. 11.
    J. Dillner and B. Kallin, Adv. Canc. Res. 50, 95 (1988).CrossRefGoogle Scholar
  12. 12.
    G. Laux, M. Perricaudet, P. J. Farrell, EMBO J. 7, 769 (1988).PubMedGoogle Scholar
  13. 13.
    L. S. Young et al., J. Gen Virol. 69, 1051 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    W. Henle et al., Proc. Natl. Acad. Sei. U.S.A. 84, 570 (1987).CrossRefGoogle Scholar
  15. 15.
    G. Rhodes et al., J. Exp. Med. 165, 1026 (1987).PubMedCrossRefGoogle Scholar
  16. 16.
    A. B. Rickinson, in The Epstein-Barr Virus: Recent Advances, M. A. Epstein and B. G. Achong Eds. (William Heinemann, London, 1986) pp 75–125.Google Scholar
  17. 17.
    G. Tosato, Adv. Canc. Res. 49, 75 (1987).CrossRefGoogle Scholar
  18. 18.
    Q. Y. Yao, A. B. Rickinson, M. A. Epstein, Int. J. Cancer 35, 35 (1985).PubMedCrossRefGoogle Scholar
  19. 19.
    L. A. Morrison et al., J. Exp. Med. 163, 903 (1986).PubMedCrossRefGoogle Scholar
  20. 20.
    D. O. Ulaeto et al., Eur. J. Immunol. (in press).Google Scholar
  21. B. Carreno, G. R. Pearson, R. J. Hartzman, (submitted for publication).Google Scholar
  22. 22.
    D. J. Moss et al., Eur. J. Immunol. 11, 686 (1981).PubMedCrossRefGoogle Scholar
  23. 23.
    I. S. Misko et al., Int. J. Cancer 33, 239 (1984).PubMedCrossRefGoogle Scholar
  24. 24.
    D. J. Moss et al., Nature 331, 719 (1988).PubMedCrossRefGoogle Scholar
  25. 25.
    R. J. Murray et al., J. Virol. 62, 3747 (1988).PubMedGoogle Scholar
  26. 26.
    F. Gotch et al., J. Exp. Med. 165, 408 (1987).PubMedCrossRefGoogle Scholar
  27. 27.
    A. B. Rickinson, Q. Y. Yao, L. E. Wallace, Brit. Med. Bull. 41, 75 (1985).PubMedGoogle Scholar
  28. Q. Y. Yao et al., Int. J. Cancer, (in press).Google Scholar

Copyright information

© The Humana Press Inc. 1989

Authors and Affiliations

  • A. B. Rickinson
    • 1
  1. 1.Cancer Research Campaign Laboratories, Department of Cancer StudiesUniversity of BirminghamBirminghamUK

Personalised recommendations